STATEN ISLAND, N.Y.,
Oct. 27, 2021 /PRNewswire/
-- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the
"Company"), a clinical stage biopharmaceutical company developing a
new class of antibiotics for difficult-to-treat bacterial
infections, announced today that the Company will release its 2021
third quarter financial results on Monday,
November 15, 2021, at 8:30 am
ET before the U.S. financial markets open.
David P. Luci, President and
Chief Executive Officer, and Robert G.
Shawah, Chief Financial Officer, will host a conference call
to discuss the results and provide a business update as
follows:
Date: Monday, November 15,
2021
Time: 8:30 a.m. ET
Toll free (U.S. and International): 877-790-1503
Conference ID: 13724324
About Ibezapolstat
Ibezapolstat is a novel, orally administered antibiotic being
developed as a Gram-Positive Selective Spectrum (GPSS™)
antibacterial. It is the first of a new class of DNA
polymerase IIIC inhibitors under development by Acurx to treat
bacterial infections. Ibezapolstat's unique spectrum of
activity, which includes C. difficile but spares other
Firmicutes and the important Actinobacteria phyla, appears to
contribute to the maintenance of a healthy gut microbiome.
In June 2018, ibezapolstat was
designated by the U.S. Food and Drug Administration (FDA) as a
Qualified Infectious Disease Product (QIDP) for the treatment of
patients with CDI and will be eligible to benefit from the
incentives for the development of new antibiotics established under
the Generating New Antibiotic Incentives Now (GAIN) Act. In
January 2019, FDA granted "Fast
Track" designation to ibezapolstat for the treatment of patients
with CDI. The Company successfully completed Phase 1 and
Phase 2a clinical trials of ibezapolstat and is preparing to start
enrollment of its Phase 2b
vancomycin-controlled efficacy study in a 1:1 randomized trial of a
total of 64 patients with CDI.
The CDC has designated C. difficile as an urgent threat
highlighting the need for new antibiotics to treat CDI.
About Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals is a clinical stage biopharmaceutical
company focused on developing new antibiotics for difficult to
treat infections. The Company's approach is to develop antibiotic
candidates that target the DNA polymerase IIIC enzyme and its
R&D pipeline includes antibiotic product candidates that target
Gram-positive bacteria, including Clostridioides difficile,
methicillin-resistant Staphylococcus aureus (MRSA),
vancomycin resistant Enterococcus (VRE) and drug-resistant
Streptococcus pneumoniae (DRSP). To learn more about Acurx
Pharmaceuticals and its product pipeline please visit
www.acurxpharma.com.
Investor Contact:
Acurx Pharmaceuticals, Inc.
David P. Luci, President &
CEO
Tel: 917-533-1469
Email: davidluci@acurxpharma.com
View original
content:https://www.prnewswire.com/news-releases/acurx-pharmaceuticals-to-discuss-2021-third-quarter-financial-results-on-november-15-2021-conference-call-and-provide-business-update-301408715.html
SOURCE Acurx Pharmaceuticals, Inc.